MarketCapExport financials
Apollo Medical Holdings (AMEH)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Apollo Medical Holdings Income Statement 2025-2010 | AMEH
Brief overview of financial results at Apollo Medical Holdings
The comparison covers a five-year financial horizon. Revenue reported by Apollo Medical Holdings was $687 million at the beginning of the period and $3.2 billion at the end. Overall revenue changed by +363%, equal to an annualized rate of about 35.9%. The company expanded its revenue base at a high speed.
The gross result shifted from 148 million dollars to 342 million dollars, or +130.8%. Direct costs outpaced revenue, limiting the benefit of changes in sales. Comparing the endpoints gives gross margins of 21.5% and 10.7%. Weakening gross profitability reduces the quality of the top-line trend.
EBITDA changed from $98.9 million to $124 million (+25.7%). Changes in revenue did not translate into comparable EBITDA performance. The EBITDA share of revenue changed from 14.4% to 3.9%. Cost pressure reduced operating profitability.
Over the period, net income shifted from 37.7 million dollars to 24 million dollars (−36.3%). Lower net income weakens the overall financial picture.
Overall conclusion
The current trajectory does not yet confirm a sustainable recovery. The constructive conclusion rests on sales growth. The overall view is constrained by a narrow EBITDA buffer, a declining EBITDA margin and a weaker final result. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement Apollo Medical Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
- | - | 1.9 B | 1.63 B | 2.11 B | 904 M | 631 M | 625 M | 59.7 M | 34.7 M | 24.3 M | 23.5 M | 22 M | 3.49 M | 5.22 M | - |
Shares |
49.1 M | 47.6 M | 46.6 M | 45 M | 43.8 M | 36.5 M | 34.7 M | 32.9 M | 6.03 M | 5.88 M | 4.86 M | 4.7 M | 3.48 M | 2.91 M | 2.75 M | - |
Historical Prices |
- | - | 40.8 | 36.2 | 48.1 | 24.8 | 17.5 | 19.5 | 19.9 | 9 | 5.5 | 4.3 | 5.3 | 6.3 | 1.2 | - |
Net Income |
24 M | 50 M | 58 M | 46 M | 46 M | 37.7 M | 14.1 M | 10.8 M | -8.97 M | -9.34 M | -1.8 M | -4.56 M | -8.9 M | -720 K | -156 K | - |
Revenue |
3.18 B | 2.03 B | 1.39 B | 1.14 B | 774 M | 687 M | 555 M | 515 M | 57.4 M | 44 M | 33 M | 10.5 M | 7.78 M | 5.11 M | 3.9 M | - |
Cost of Revenue |
2.84 B | 1.76 B | 1.17 B | 945 M | 596 M | 539 M | 468 M | 361 M | 273 M | - | - | - | - | - | - | - |
Gross Profit |
342 M | 271 M | 215 M | 199 M | 178 M | 148 M | 87.6 M | 154 M | 8.69 M | 10 M | 10.9 M | 1.41 M | 1.46 M | 978 K | 582 K | - |
Operating Income |
78.5 M | 89.4 M | 84.6 M | 104 M | 98.2 M | 80.5 M | 32.4 M | 88.4 M | 35.1 M | 11.7 M | -694 K | -3.91 M | -2.08 M | -413 K | 4.02 K | - |
Interest Expense |
-2.79 M | 4.88 M | 16.1 M | 7.92 M | 5.39 M | 9.5 M | 4.73 M | 561 K | 79.7 K | 61.6 K | 1.33 M | 679 K | 930 K | 304 K | 126 K | - |
EBITDA |
124 M | 117 M | 102 M | 122 M | 116 M | 98.9 M | 52.7 M | 112 M | -9.89 M | -6.91 M | -360 K | -3.88 M | -2.06 M | -401 K | 15.2 K | - |
Operating Expenses |
263 M | 182 M | 130 M | 95.2 M | 79.6 M | 67.5 M | 53.2 M | 61.3 M | 19.2 M | 17.3 M | 11.6 M | 5.32 M | 3.54 M | 1.39 M | 578 K | - |
General and Administrative Expenses |
217 M | 154 M | 113 M | 77.7 M | 62.1 M | 49.1 M | 41.5 M | 43.4 M | 18.6 M | 17 M | 11.3 M | 5.29 M | 3.52 M | 1.38 M | 567 K | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Apollo Medical Holdings
| 2026-Q3 | 2026-Q2 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
49.2 M | 49.1 M | 70.4 K | 49.2 M | 49.2 M | 48.9 M | 75.9 K | 47.7 M | 47.6 M | 47.3 M | 25.9 M | 46.5 M | 46.5 M | 46.6 M | 176 K | 44.9 M | 44.9 M | 44.7 M | 221 K | 44.3 M | 44.2 M | 42.3 M | 378 K | 36.4 M | 36.1 M | 36 M | 153 K | 34.6 M | 34.5 M | 34.5 M | 221 K | 32.9 M | 32.7 M | 32.4 M | 32.3 M | 6.03 M | 6.02 M | 25.1 M | 6.03 M | 5.37 M | 5.97 M | 4.86 M | -44.1 M | 48.8 M | 4.91 M | 4.91 M | 4.88 M | 4.9 M | 4.91 M | 4.72 M | 42.1 M | 38 M | 38 M | 34.8 M | 34.8 M | 33.4 M | 31 M | 30 M | 29.3 M | 29.3 M | 29 M | 28.6 M |
Net Income |
20.3 M | 18.5 M | 6.56 M | 1.08 M | 10.2 M | 13.1 M | -7.78 M | 19 M | 21.9 M | 16.9 M | -94 K | 28 M | 17.5 M | 12.5 M | -883 K | 23.9 M | 11.3 M | 11.4 M | -18.2 M | -5.23 M | 56.3 M | 13.2 M | 12.9 M | 25.4 M | 81 M | 2.99 M | -1.28 M | 10.7 M | 10.7 M | -2.45 M | -1.94 M | 38.6 M | 7.87 M | 15.7 M | 35.8 M | -1.48 M | -1.47 M | 4.35 M | -1.73 M | -1.53 M | -2.67 M | -2.23 M | 15.1 K | -1.39 M | 1.54 M | -1.51 M | -1.69 M | -1.99 M | -301 K | -766 K | -1.16 M | -1.01 M | -1.53 M | -849 K | -823 K | -4.72 M | -3.2 M | -157 K | -427 K | 58.2 K | -123 K | -229 K |
Revenue |
1.02 B | 973 M | 951 M | 956 M | 655 M | 965 M | 665 M | 479 M | 486 M | 404 M | 353 M | 348 M | 348 M | 337 M | 294 M | 317 M | 270 M | 263 M | 195 M | 227 M | 176 M | 176 M | 177 M | 180 M | 165 M | 165 M | 179 M | 156 M | 130 M | 95.8 M | 107 M | 167 M | 123 M | 124 M | - | 15.7 M | 14.6 M | 85.3 M | 15.7 M | 10.7 M | 27 M | 10.2 M | 9.59 M | 7.64 M | 11.7 M | 4.09 M | 7.64 M | 23.4 M | 15.8 M | 2.34 M | 2.84 M | 2.61 M | 2.59 M | 2.45 M | 2.53 M | 1.97 M | 1.65 M | 1.63 M | 1.55 M | 1.43 M | 1.09 M | 1.04 M |
Cost of Revenue |
900 M | 868 M | 855 M | 859 M | 577 M | 859 M | 615 M | 405 M | 413 M | 330 M | 314 M | 275 M | 293 M | 289 M | 253 M | 241 M | 230 M | 221 M | 172 M | 147 M | 136 M | 141 M | 137 M | 122 M | 136 M | 144 M | 152 M | 131 M | 101 M | 83.4 M | 80.5 M | 96.3 M | 99.7 M | 84.6 M | - | 66.7 M | 66.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
124 M | 104 M | 95 M | 97.2 M | 78 M | 106 M | 50.5 M | 73.5 M | 73.5 M | 74 M | 39 M | 72.8 M | 55.3 M | 47.8 M | 41.1 M | 76.2 M | 39.6 M | 42.5 M | 23.3 M | 79.6 M | 39.4 M | 35.4 M | 39.7 M | 58.3 M | 29.1 M | 20.9 M | 26.9 M | 24.9 M | 28.7 M | 12.3 M | 26 M | 70.5 M | 23 M | 39.3 M | - | -51.1 M | -52 M | - | - | - | - | - | - | - | - | - | - | - | - | - | 131 K | 465 K | 227 K | 586 K | 547 K | 166 K | 444 K | 303 K | 406 K | 335 K | 154 K | 92.2 K |
Operating Income |
39.9 M | 34.3 M | 18.4 M | 19.2 M | 20.3 M | 28.5 M | 720 K | 28.4 M | 30.1 M | 30.1 M | -3.87 M | 39.1 M | 27 M | 22.4 M | 12.6 M | 50.1 M | 15.4 M | 26.2 M | 2.25 M | 53.2 M | 21 M | 21.8 M | 25.9 M | 37.4 M | 12.9 M | 4.36 M | 10.9 M | 10.1 M | 14.7 M | -3.31 M | 2 M | 56.6 M | 7.15 M | 22.7 M | 23.5 M | -1.68 M | -2.17 M | 15.7 M | -1.68 M | -1.46 M | -3.94 M | -1.66 M | 165 K | -1.53 M | 1.86 M | -1.19 M | -1.53 M | -860 K | 672 K | -547 K | -1.02 M | -813 K | -1.36 M | -712 K | -525 K | -1.44 M | -63 K | -53.2 K | -269 K | 126 K | -83.3 K | -187 K |
Interest Expense |
1.23 M | -2.3 M | 699 K | 445 K | 1.14 M | 662 K | 353 K | 2.67 M | 6.13 M | -4.28 M | 1.86 M | 1.88 M | 1.18 M | 1.2 M | 1.62 M | -1.32 M | 3.03 M | 613 K | 10.3 M | 500 K | -15.9 M | 1.3 M | -437 K | 130 K | 1.28 M | 102 K | 198 K | 2.62 M | 24 K | 187 K | 737 K | 609 K | 188 K | 88 K | -65.6 K | 888 | 10.6 K | 811 | 9.99 K | -100 K | 5.71 K | 101 K | -48.7 K | 113 K | -58.4 K | -2.48 K | 363 K | 969 K | 606 K | 185 K | 41.4 K | 9.48 K | -924 | -246 | -37.9 K | 207 | 455 | -5 | 247 | 49 | 1.48 K | 40.9 K |
EBITDA |
53.7 M | 48.1 M | 32.5 M | 33.4 M | 26.5 M | 42.4 M | 8.32 M | 35.1 M | 37 M | 37 M | -670 K | 42.3 M | 30.3 M | 25.4 M | 15.7 M | 53.5 M | 18.9 M | 29.9 M | 6.05 M | 57.3 M | 24.7 M | 25.6 M | 29.6 M | 41.4 M | 17 M | 8.56 M | 15.1 M | 14.4 M | 18.6 M | 593 K | 6.3 M | 60.8 M | 11.3 M | 27.8 M | 23.5 M | -1.53 M | -2 M | 20.5 M | -1.53 M | -1.31 M | -3.6 M | -1.64 M | 125 K | -1.42 M | 1.98 M | -1.17 M | -1.34 M | -460 K | 877 K | -541 K | -1.04 M | -807 K | -1.35 M | -705 K | -540 K | -1.43 M | -58.1 K | -48.4 K | -266 K | 130 K | -80.8 K | -184 K |
Operating Expenses |
83.7 M | 69.7 M | 76.6 M | 78 M | 57.6 M | 77.2 M | 49.8 M | 45.1 M | 43.4 M | 43.8 M | 42.9 M | 33.7 M | 28.3 M | 25.5 M | 28.5 M | 26.1 M | 24.2 M | 16.3 M | 21 M | 26.5 M | 18.4 M | 13.7 M | 13.8 M | 20.9 M | 16.2 M | 16.5 M | 168 M | 146 M | 115 M | 99.1 M | 105 M | 110 M | 116 M | 101 M | 27 M | 17.4 M | 16.8 M | 69.7 M | 17.4 M | 12.1 M | 30.9 M | 11.9 M | 9.42 M | 9.17 M | 9.81 M | 5.28 M | 9.17 M | 24.3 M | 15.1 M | 2.88 M | 10.2 M | 1.28 M | 1.59 M | 1.3 M | 1.07 M | 1.6 M | 507 K | 356 K | 676 K | 209 K | 238 K | 280 K |
General and Administrative Expenses |
68 M | 54.2 M | 60.2 M | 62.4 M | 50.7 M | 61.7 M | 41.6 M | 37.8 M | 36 M | 38.7 M | 37.9 M | 29.4 M | 24.1 M | 21.2 M | 24.4 M | 21.4 M | 19.9 M | 11.9 M | 16.6 M | 21.8 M | 14.2 M | 9.46 M | 9.46 M | 16.3 M | 11.6 M | 11.8 M | 11.5 M | 7.95 M | 11.8 M | 10.3 M | 11.9 M | 9.04 M | 10.9 M | 11.3 M | 5.22 M | 4.49 M | 4.46 M | 5.21 M | 4.49 M | 3.51 M | 8.29 M | 4.24 M | 2.93 M | 2.89 M | 3.45 M | 2.01 M | 2.89 M | 8.35 M | 5.46 M | 827 K | 1.14 M | 1.27 M | 1.58 M | 1.29 M | 1.07 M | 1.6 M | 502 K | 352 K | 673 K | 205 K | 235 K | 276 K |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Apollo Medical Holdings (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Russia
Germany
Britain
China
